Sentence: This Phase I , randomized , open-label study evaluated the gastric pH-altering effects of omeprazole , a proton pump inhibitor , and the CYP3A enzyme/P-glycoprotein (Pgp)-inhibitory effects of ritonavir , an HIV protease inhibitor , on the pharmacokinetics and safety of the hepatitis C virus ( HCV ) non-structural protein 5A ( NS5A ) inhibitor GSK2336805 in healthy male and female subjects .
Drug combination annotation:
[{'class': 'POS', 'spans': ['omeprazole', 'ritonavir', 'GSK2336805'], 'is_context_needed': True}]